Stay updated on M7824 and Topotecan in Relapsed SCLC Clinical Trial
Sign up to get notified when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.

Latest updates to the M7824 and Topotecan in Relapsed SCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded a Locations section and Maryland as a location. Updated from revision v3.3.2 to v3.3.3, and removed the Maryland Locations entry and the HHS Vulnerability Disclosure.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision changed from v3.3.1 to v3.3.2, which appears to be an administrative metadata update and does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check37 days agoChange DetectedRevision history updated from v3.2.0 to v3.3.1; no substantive changes to the study details observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page removed the funding-status notice about potential delays due to government funding, removing a site-wide operational alert. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check59 days agoChange DetectedNo additions or deletions of significant content were detected, and the page content remains unchanged.SummaryDifference0.3%

- Check87 days agoChange DetectedMajor update to display a government-operation status notice and newer version tag (v3.2.0); removal of an old resource entry (Small cell lung carcinoma) and older version tag (v3.0.2).SummaryDifference2%

Stay in the know with updates to M7824 and Topotecan in Relapsed SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the M7824 and Topotecan in Relapsed SCLC Clinical Trial page.